<DOC>
	<DOCNO>NCT00617799</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look biomarkers predict response high-dose aldesleukin patient metastatic kidney cancer metastatic melanoma .</brief_summary>
	<brief_title>Biomarkers That Predict Response High-Dose Aldesleukin Patients With Metastatic Kidney Cancer Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine relationship peripheral blood lymphocyte phenotype pattern patient metastatic renal cell carcinoma metastatic melanoma response high-dose aldesleukin ( IL-2 ) . - Determine relationship peripheral blood mononuclear cell gene microarray pattern patient metastatic renal cell carcinoma metastatic melanoma response high-dose IL-2 . - Determine frequency mutation gene encode IL-2 receptor A B . OUTLINE : Patients receive high-dose aldesleukin ( IL-2 ) part standard treatment day 1 8 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients undergo blood collection baseline , prior begin course 2 , 4 week completion course 2 . Samples analyze use peripheral blood cytometry , gene microarray analysis , IL-2 receptor single-nucleotide polymorphism technique .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic renal cell carcinoma metastatic melanoma Must receive treatment highdose aldesleukin part standard therapy PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>